Related Experiment Video

Updated: Jun 16, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

[Impaired cognitive function in hepatitis C virus infection]

Signe Groth Renvillard1, Peter Derek Christian Leutscher, Simon Hjerrild

  • 1Center for Psykiatrisk Forskning, Arhus Universitetshospital, Risskov, DK-8240 Risskov, Denmark. signrenv@rm.dk

Ugeskrift for Laeger
|February 4, 2010
PubMed

Insights

Hepatitis C virus (HCV) infection impairs cognitive function even before cirrhosis develops. Doctors should inform patients about these cognitive deficits, as it is unknown if they improve after HCV eradication.

Area of Science:

  • Neuroscience
  • Hepatology
  • Infectious Diseases

Context:

  • Hepatitis C virus (HCV) infection is frequently associated with cognitive impairment.
  • Cognitive deficits manifest in the pre-cirrhotic stage, impacting daily functioning.
  • Potential causes include direct viral toxicity or HCV-induced neuroinflammation.

Purpose:

  • To highlight the prevalence and impact of cognitive dysfunction in HCV patients.
  • To emphasize the need for clinical awareness and patient education regarding cognitive deficits.
  • To identify the knowledge gap concerning cognitive function after viral eradication.

Summary:

  • HCV infection leads to cognitive impairment, potentially through direct viral effects or neuroinflammation.
  • These deficits are observable before the development of cirrhosis and affect patient functionality.
  • Further research is needed to determine if cognitive function recovers post-HCV treatment.

Impact:

  • Enhances understanding of HCV's neurological consequences.
  • Promotes informed patient care and management strategies for HCV-associated cognitive issues.
  • Guides future research on the long-term effects of HCV eradication on cognitive health.

More Related Videos

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...